First Patient Treated in Groundbreaking Armored CAR T-Cell Therapy Trial for Ovarian Cancer

First-in-Human Clinical Trial Targets Chemotherapy-Resistant Ovarian Cancer

Roswell Park Comprehensive Cancer Center and Generate Biomedicines have announced dosing the first patient in a phase 1 clinical trial (NCT07489287) evaluating GB-5267, an investigational autologous IL-18 armored CAR T-cell therapy designed specifically for ovarian cancer1

1

. This first-in-human clinical trial represents a significant step in extending CAR T-cell therapy benefits beyond blood cancers to solid tumors, where the approach has historically faced substantial obstacles. The trial recruits patients whose disease has returned after treatment or does not respond to platinum-based chemotherapy, the standard first-line treatment for ovarian cancer2

2

.

Targeting MUC16 in Recurrent Ovarian Cancer

GB-5267 targets MUC16, an antigen over-expressed by more than 80% of ovarian tumors that helps them grow, spread, and hide from the immune system1

1

. Led by Principal Investigator Emese Zsiros, MD, PhD, Chair of Gynecologic Oncology at Roswell Park, the study will evaluate the safety and tolerability of this novel approach. Each patient's T cells will be collected, genetically engineered, and expanded in Roswell Park's GMP Engineering & Cell Manufacturing Facility before being returned to the patient to mount a targeted attack against tumor cells. This matters because recurrent ovarian cancer often no longer responds to chemotherapy, leaving patients with limited options and a five-year relative survival rate of just 51.6%1

1

.

Armored CAR T Therapy Overcomes Tumor Microenvironment Barriers

While CAR T-cell therapy has transformed outcomes in blood cancers, solid tumors have posed unique challenges due to their suppressive tumor microenvironment—a protective barrier that prevents immune cells from entering or recognizing tumors. The investigators are armoring the T cells with IL-18, a cytokine that helps protect them from immune suppression within solid tumors, according to Marco Davila, MD, PhD, Senior Vice President and Associate Director for Translational Research at Roswell Park2

2

. Because ovarian cancer spreads through the peritoneal cavity, the armored CAR T therapy will be delivered both intravenously and directly into the peritoneal cavity, concentrating the immune response where needed without the toxicity of high-dose chemotherapy1

1

.

AI-Driven Therapy Design Optimizes T-Cell Persistence

Generate Biomedicines engineered GB-5267 using artificial intelligence to design and evaluate CAR architectures at scale based on how T cells actually behave, rather than relying solely on binding affinity as a proxy for performance2

2

. The AI-driven therapy was computationally designed to optimize three interdependent functions critical for CAR T-cell performance in solid tumors: potency (the ability to kill MUC16-expressing tumor cells), proliferation (the ability to expand into a larger T-cell population), and T-cell persistence (the ability to remain active over time in a suppressive tumor microenvironment)1

1

. Dinesh de Alwis, PhD, Senior Vice President and Head of Clinical Drug Development at Generate Biomedicines, emphasized that recognizing a tumor antigen is only part of the challenge—a CAR T cell that kills but does not expand or persist offers only a partial solution.

Eliminating Lymphodepletion and Chemotherapy Side Effects

Unlike many CAR T-cell approaches, this study will not require lymphodepletion, the process that uses chemotherapy to reduce a patient's original immune cells to make space for engineered cells1

1

. This means patients enrolled in the clinical trial will avoid exposure to the side effects associated with chemotherapy, a significant advantage for those already dealing with chemotherapy-resistant ovarian cancer. Watch for early safety data from this phase 1 trial, which could determine whether GB-5267's function-first design translates to clinical success and potentially opens new pathways for treating other solid tumors where CAR T-cell therapy has struggled to gain traction.